» Sign in

TPO

Thrombopoietin, Megakaryocyte colony stimulating factor

mouse, recombinant, E. coli

Product Cat. No. Amount Price (EUR) Buy / Note
TPO PR-688 10 μg 253,00 Add to Basket/Quote Add to Notepad

For in vitro use only!

Shipping: shipped at ambient temperature

Storage Conditions: store at -20 °C
avoid freeze/thaw cycles

Shelf Life: 12 months

Molecular Weight: 17 kDa

Accession number: P40226

Accession number: P40226

Purity: > 95 % (SDS-PAGE)

Form: lyophilized

Solubility: It is recommended to reconstitute the lyophilized TPO in sterile bidest H2O not less than 100 μg/ml. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).

Activity: ED50: 0.05-0.015 ng/ml determined by the dose dependent proliferation of MO7e cells. The optimal concentration for each specific application should be determined by an initial dose-response assay.

Description:
Thrombopoietin (TPO) and the TPO receptor (Mpl) are the key regulators of platelet mass and are required for both stem cell proliferation and for the terminal differentiation of platelets. TPO may be a potent regulator of ovarian function (e.g. proliferation, apoptosis and the secretion of peptide hormones, steroids, growth factors and growth factor-binding protein, as well as of the expression of some intracellular messengers). Furthermore the importance of PKA in controlling these functions and in mediating the effects of TPO on ovarian cells was demonstrated. Thrombopoietin Mouse Recombinant produced in E.coli is a single, non-glycosylated soluble polypeptide chain containing 174 amino acids and having a molecular mass of 17kDa. The TPO is purified by proprietary chromatographic techniques.

Amino Acid Sequence: The sequence of the first five N-terminal amino acids was determined and was found to be Ser-Pro-Val-Ala-Pro.

Selected References:
Moliterno et al. (2004) Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis. Proc. Natl. Acad. Sci. USA. 101:11444.
Orita et al. (2005) A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor. Blood. 105:562.
Kirito et al. (2004) Thrombopoietin induces HOXA9 nuclear transport in immature hematopoietic cells: potential mechanism by which the hormone favorably affects hematopoietic stem cells. Mol. Cell. Biol. 24:6751.
Antonchuk et al. (2004) Synergistic effects on erythropoiesis, thrombopoiesis, and stem cell competitiveness in mice deficient in thrombopoietin and steel factor receptors. Blood. 104:1306.
Rouleau et al. (2004) A functional erythropoietin receptor is necessary for the action of thrombopoietin on erythroid cells lacking c-mpl. Exp. Hematol. 32:140.
Carpinelli et al. (2004) Suppressor screen in Mpl-/- mice: c-Myb mutation causes supraphysiological production of platelets in the absence of thrombopoietin signaling. Proc. Natl. Acad. Sci. USA 101:6553.
Bradley et al. (2004) Hematopoietic-repopulating defects from STAT5-deficient bone marrow are not fully accounted for by loss of thrombopoietin responsiveness. Blood. 103:2965.